FLAGYL 250 MG TABLETS Israel - Inggeris - Ministry of Health

flagyl 250 mg tablets

sanofi israel ltd - metronidazole - film coated tablets - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria, lambliasis.

SUPREFACT DEPOT 3-MONTHS Israel - Inggeris - Ministry of Health

suprefact depot 3-months

sanofi - aventis israel ltd - buserelin acetate - rods for implant - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).

STILNOX 10 MG TABLETS Israel - Inggeris - Ministry of Health

stilnox 10 mg tablets

sanofi israel ltd - zolpidem tartrate - film coated tablets - zolpidem tartrate 10 mg - zolpidem - zolpidem - indications are limited to treatment of severe sleep disorders in the following cases: - occasional insomnia - transient insomnia.

KAYEXALATE Israel - Inggeris - Ministry of Health

kayexalate

sanofi israel ltd - polystyrene sulphonate sodium - powder for suspension - polystyrene sulphonate sodium 99.934 % - polystyrene sulfonate - polystyrene sulfonate - treatment of hyperkalemia.

TRITACE 1.25 MG Israel - Inggeris - Ministry of Health

tritace 1.25 mg

sanofi israel ltd - ramipril - tablets - ramipril 1.25 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

TRITACE 2.5 MG Israel - Inggeris - Ministry of Health

tritace 2.5 mg

sanofi israel ltd - ramipril - tablets - ramipril 2.5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

TRITACE 5 MG Israel - Inggeris - Ministry of Health

tritace 5 mg

sanofi israel ltd - ramipril - tablets - ramipril 5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Hexaxim Suspension for Injection Malaysia - Inggeris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hexaxim suspension for injection

sanofi-aventis (malaysia) sdn. bhd. - diphtheria toxoid; filamentous haemagglutin ( fha ); haemophilus influenza type b conjugate; hepatitis b surface antigen purified; pertussis toxoid ( pt); poliomyelitis, trivalent, inactivated, whole virus; tetanus toxoid -

ROVAMYCIN Israel - Inggeris - Ministry of Health

rovamycin

sanofi israel ltd - spiramycin - film coated tablets - spiramycin 1.5 miu - spiramycin - respiratory tract infections, infections caused by clamydia, cryptosporidiosis pregnancy toxoplasmosis.

RULID 150 MG Israel - Inggeris - Ministry of Health

rulid 150 mg

sanofi - aventis israel ltd - roxithromycin - film coated tablets - roxithromycin 150 mg - roxithromycin - for the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ent bronchopulmonary, genital and skin manifestations.